Development and validation of new plant extracts to counter metabolic and hepatic disorders by modulating the intestinal microbiota.

 

Obesity and associated hepatic and metabolic disorders will affect a majority of people throughout the world. Innovative dietary strategies have to be developed to address the growing needs of people suffering from them.

 

Advancements tend to show that our intestinal microbiota make a major contribution to the protective state against obesity, chronic inflammation and associated disorders.

At the same time, low-grade inflammation plays a prominent role in triggering such disorders. No nutritional treatment at this time offers products with complementary and validated metabolic effects to target the different disorders associated with obesity.

The identification of nutrients capable of providing protection against the phenomenon of dysbiosis will undoubtedly constitute a way forward in the management of metabolic syndrome.

The aim of the Nutrimicrobiota is to develop plant extracts that act on the intestinal microbiota as well as on complementary action mechanisms.

 

These nutritional ingredients are believed to have effects that prevent the onset of metabolic disorders and thus to improve intestinal health.

 

Reaching these objectives will enable the partners to provide an innovative approach and/or new products to counter metabolic syndrome.

Consortium